Gemphire Shares Drop on Disappointing Phase II Results for LDL Drug


Shares of Gemphire Therapeutics plunged more than 51 percent in morning trading after the company’s Phase IIb anti-cholesterol drug gemcabene failed to meet analyst expectations.
Source link